Adjuvant therapy with toceranib for hepatocellular carcinoma and cholangiocarcinoma in a Pomeranian
Copyright: © 2023 Choi et al..
A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography revealed a mass with multiple nodules on the right hepatic medial lobe adjacent to the caudal vena cava; histopathology confirmed mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of incomplete resection, adjuvant therapy was recommended. As tumour cells showed PDGFR-α, c-Kit, and FGFR1 overexpression, the anticancer effect of tyrosine kinase inhibitors was evaluated on the cells; toceranib was the most effective and was administered starting with an extra-labelled dose. The dog remained stable for 2.3 years with mild adverse effects. To our knowledge, this is the first successful clinical application of toceranib in a dog with mixed HCC-CC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Veterinarni medicina - 68(2023), 2 vom: 08. Feb., Seite 83-89 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Lee [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.17221/49/2022-VETMED |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368222500 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368222500 | ||
| 003 | DE-627 | ||
| 005 | 20240210233352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.17221/49/2022-VETMED |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM368222500 | ||
| 035 | |a (NLM)38332765 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Lee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adjuvant therapy with toceranib for hepatocellular carcinoma and cholangiocarcinoma in a Pomeranian |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2023 Choi et al. | ||
| 520 | |a A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography revealed a mass with multiple nodules on the right hepatic medial lobe adjacent to the caudal vena cava; histopathology confirmed mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of incomplete resection, adjuvant therapy was recommended. As tumour cells showed PDGFR-α, c-Kit, and FGFR1 overexpression, the anticancer effect of tyrosine kinase inhibitors was evaluated on the cells; toceranib was the most effective and was administered starting with an extra-labelled dose. The dog remained stable for 2.3 years with mild adverse effects. To our knowledge, this is the first successful clinical application of toceranib in a dog with mixed HCC-CC | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a anticancer effect | |
| 650 | 4 | |a biliary carcinoma | |
| 650 | 4 | |a canine | |
| 700 | 1 | |a Choi, Jin-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Hun-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Kieun |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Kyong-Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jung-Hyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Veterinarni medicina |d 1971 |g 68(2023), 2 vom: 08. Feb., Seite 83-89 |w (DE-627)NLM000011282 |x 0375-8427 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2023 |g number:2 |g day:08 |g month:02 |g pages:83-89 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17221/49/2022-VETMED |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2023 |e 2 |b 08 |c 02 |h 83-89 | ||